The intent of CAD-RADS -Coronary Artery Disease Reporting and Data System is to create a standardized method to communicate findings of coronary CT angiography (coronary CTA) in order to facilitate decision-making regarding further patient management. The suggested CAD-RADS classification is applied on a per-patient basis and represents the highest-grade coronary artery lesion documented by coronary CTA. It ranges from CAD-RADS 0 (Zero) for the complete absence of stenosis and plaque to CAD-RADS 5 for the presence of at least one totally occluded coronary artery and should always be interpreted in conjunction with the impression found in the report. Specific recommendations are provided for further management of patients with stable or acute chest pain based on the CAD-RADS classification. The main goal of CAD-RADS is to standardize reporting of coronary CTA results and to facilitate communication of test results to referring physicians along with suggestions for subsequent patient management. In addition, CAD-RADS will provide a framework of standardization that may benefit education, research, peer-review and quality assurance with the potential to ultimately result in improved quality of care.
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The intent of CAD-RADS -Coronary Artery Disease Reporting and Data System is to create a standardized method to communicate findings of coronary CT angiography (coronary CTA) in order to facilitate decision-making regarding further patient management. The suggested CAD-RADS classification is applied on a per-patient basis and represents the highest-grade coronary artery lesion documented by coronary CTA. It ranges from CAD-RADS 0 (Zero) for the complete absence of stenosis and plaque to CAD-RADS 5 for the presence of at least one totally occluded coronary artery and should always be interpreted in conjunction with the impression found in the report. Specific recommendations are provided for further management of patients with stable or acute chest pain based on the CAD-RADS classification. The main goal of CAD-RADS is to standardize reporting of coronary CTA results and to facilitate communication of test results to referring physicians along with suggestions for subsequent patient management. In addition, CAD-RADS will provide a framework of standardization that may benefit education, research, peer-review and quality assurance with the potential to ultimately result in improved quality of care.
Abbreviations
CAD-RADS = Coronary Artery Disease Reporting and Data System
Coronary CTA = coronary CT angiography BI-RADS = Breast Imaging Reporting and Data System LI-RADS = Liver Imaging Reporting and Data System Lung-RADS = Lung CT Screening Reporting and Data System PI-RADS = Prostate Imaging Reporting and Data System ICA = invasive coronary angiography CAD = coronary artery disease ACS = acute coronary syndrome N = non-diagnostic S = stent G = graft V = vulnerability M A N U S C R I P T
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Introduction
Coronary CT Angiography (coronary CTA) has made substantial progress since the introduction of 64-slice CT scanners approximately 10 years ago (1), both concerning imaging technology and clinical validation. In parallel, several professional societies have issued guidelines, expert consensus documents, and Appropriateness Criteria for coronary CTA (2-8). To maximize the clinical impact of coronary CTA, imaging protocols must be optimized with respect to image quality, diagnostic accuracy, and radiation dose. Training and interpretation standards are important. Finally, standardized reporting is helpful to decrease variability among practitioners and may provide further benefit by linking the final impression in the report with suggestions for further patient management.
Other fields in medical imaging (notably, breast imaging with BI-RADS) have introduced standardized reporting linked with actionable information to guide next steps in patient management (9). BI-RADS standardized reporting of screening mammograms allows clinicians to interpret the clinical relevance of reported findings and to take action. Moreover, BI-RADS facilitates collection of data for registries and databases, allowing better tracking of individual patient outcomes with specific imaging findings.
Next to BI-RADS, standardized reporting has been introduced for several other fields. They include, for example:
 LI-RADS TM (Liver Imaging Reporting and Data System) for standardization reporting in patients with chronic liver disease (10).
 Lung-RADS TM (Lung CT Screening Reporting and Data System) for standardization reporting of high-risk smokers undergoing CT lung screening (11).
 PI-RADS TM (Prostate Imaging Reporting and Data System) for multi-parametric MR imaging in the context of prostate cancer (12).
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The purpose of this document is to describe a standardized reporting system for patients undergoing coronary CTA. The report system is named CAD-RADS (Coronary Artery Disease Reporting and Data System) and is applicable to coronary CTA in patients with suspected or known coronary artery disease either in the outpatient, inpatient or emergency department setting. It includes suggestions regarding further patient management, which, obviously will always need to be seen in light of the full clinical information available to the treating physician. For the specific setting of coronary CTA in patients with acute chest pain presenting to the emergency department, certain management recommendations have been reported previously (13, 14) .
The goal of CAD-RADS, through standardization of report terminology for coronary CTA, is to improve communication between interpreting and referring physicians, facilitate research, and offer mechanisms to contribute to peer review and quality assurance, ultimately resulting in improvements to quality of care. Importantly, CAD-RADS does not substitute the impression section provided by the reading physician and should always be interpreted in conjunction with the more individual and patient-specific information found in the report.
Clinical Value of Coronary CT Angiography
Several recent prospective trials have evaluated the clinical utility of coronary CTA and the relevance of CT findings in the context of suspected stable coronary artery disease. They include the PROMISE (15) and SCOT-HEART (16) trials, which demonstrated that coronary CTA is clinically useful as an alternative to (PROMISE) or in addition to functional testing (SCOT-HEART).
Four large randomized trials (CT-STAT, ACRIN-PA, ROMICAT II and CT-COMPARE) compared coronary CTA to the current standard of care in patients with acute chest pain (17) (18) (19) (20) . Complemented by "real world" implementation data (21, 22), they consistently M A N U S C R I P T
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demonstrate the safety of a negative coronary CTA to identify patients for discharge from the emergency department.
There are some limitations to the currently mentioned available studies (for example, their over-representation of low risk patients). Other situations, such as the use of coronary CTA in patients with known coronary artery disease, have not been evaluated in appropriate clinical trials. Hence, while fully taking into account the available data, this document is based on expert consensus. This includes the suggested categories for reporting but also the suggestions for further patient management, which need to be interpreted in the context of other clinical information that is available in any given patient.
CAD-RADS Reporting System
CAD-RADS Categories
CAD-RADS categories depend on stenosis severity. For the grading of stenosis severity, a classification system suggested by the Society of Cardiovascular Computed Tomography is used (see table 1 ). Tables 2 and 3 list the categories of the CAD-RADS reporting system for   stable chest pain (table 2) and acute chest pain (table 3) . They range from CAD-RADS 0 (absence of atherosclerosis) to CAD-RADS 5 (presence of at least one total occlusion) in both settings. Categories should reflect the clinically most relevant finding per patient. Many patients with previously known CAD will include lesions that fall into this category, so that coronary CTA will need to be complemented by further tests. Additionally, coronary CTA has low accuracy for diagnosis of in-stent restenosis, particularly in stents smaller than 3.0 mm diameter. Thus, the use of coronary CTA in patients with previously known CAD should be carefully considered. Management decisions derived from coronary CTA results depend on other clinical findings as well as the patient-specific previous history, and should be made on an individual basis.
Modifiers
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CAD-RADS categories can be complemented by modifiers to indicate that a study is not fully evaluable or non-diagnostic (N) or to indicate the presence of stents (S), grafts (G), and vulnerable plaque (V).
I.
Modifier N -Non-diagnostic study "N" can be used as a modifier or as a CAD-RADS category, depending on context. If the study is not fully diagnostic (i.e. not all segments > 1.5 mm diameter can be interpreted with confidence) and a stenosis is present in a diagnostic segment, the highest stenosis should be graded in addition to the modifier N if CAD-RADS is greater than 3. For example, a patient with moderate stenosis (50-69%) in one segment and one or more non-diagnostic remote segments should be graded as CAD-RADS 3/N ( Figure 10 ) and not CAD-RADS N, since further evaluation is needed, possibly with functional imaging, and patient recommendations for anti-ischemic and preventive management apply. However, for a patient with no stenosis (zero), minimal (1-24%), or no more than mild stenosis (25-49%) in interpretable segments, CAD-RADS N should be used since Coronary CTA cannot be used to guide patient management and further evaluation to exclude obstructive coronary artery disease is still needed.
II. Modifier S -Presence of a stent
The modifier "S" indicates the presence of at least one coronary stent anywhere in the coronary system. 
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Finally, if a stent were non-evaluable, the case would be classified as CAD-RADS N/S if there is no other stenosis greater than 50% in the coronary tree. Note: CAD-RADS was created to guide management recommendations, so it does not matter whether it is the stent or a non-stented vessel that has a severe stenosis. Rather, what matters is that the patient has a severe stenosis and needs further work-up.
III. Modifier G = Presence of coronary bypass grafts:
The modifier "G" indicates the presence of at least one coronary-artery bypass graft ( Figure   12 ). A stenosis bypassed by a fully patent graft is not considered for the CAD-RADS classification. For example, if a patient has a graft to LAD, with absence of significant stenoses in the graft, distal anastomosis and run-off vessel, and demonstrates non-obstructive lesions (25-49%) in the LCX and RCA, in addition to the "expected" proximal LAD severe stenosis, then the case would be classified as: CAD-RADS 2/G. If a patient demonstrates total occlusion of a saphenous vein graft (SVG) to the RCA, and a patent LIMA to LAD and SVG to LCX, then the case would be classified as: CAD-RADS 5/G. The interpretation is that a total occlusion is present and further investigation and/or management may be required.
IV. Modifier V = Presence of "vulnerable" or high-risk plaque features
Data from recent coronary CTA studies have described vulnerable plaque characteristics that are independently associated with future ACS. They include positive remodeling, lowattenuation plaque, spotty calcification, and the napkin-ring sign (23, 24).
If a coronary plaque clearly demonstrates two or more high-risk features by coronary CTA, the modifier "V" (vulnerability) should be added (Figures 13 and 14) . High-risk features include: low attenuation plaque (less than 30 Hounsfield Units), positive remodeling, spotty calcification, and the "napkin ring sign" (see Figure 13 ). v. For a patient with severe stenosis (70-99%) in one segment and a non-diagnostic area in another segment, the study should be graded as CAD-RADS 4/N.
Presence of other cardiac or extra-cardiac findings
Patients undergoing coronary CTA may demonstrate other significant, potentially significant or non-significant cardiac or extra-cardiac findings. CAD-RADS is intended to focus solely on the classification of coronary artery stenosis and further management. However, other cardiac and extra-cardiac findings of relevance should be reported in coronary CTA studies and should be mentioned in the report text. Specific follow-up and recommendations should be included depending on the pathology.
Finally, Figure 16 provides a sample standardized reporting template for coronary CTA incorporating CAD-RADS coding.
DISCUSSION
The use of coronary CTA to assess patients with stable chest pain in the outpatient setting or acute chest pain presenting to the Emergency Department has been validated in various clinical trials. Major guidelines are incorporating the use of coronary CT angiography as appropriate for assessing low to intermediate risk patients presenting with chest pain.
Decreasing the variation in reporting is one aspect that will contribute to wider dissemination in clinical practice, minimize error and to ultimately improve patient outcome. The main goal of the CAD-RADS classification system is to propose a reporting structure that provides consistent categories for final assessment, along with suggestions for further management.
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CAD-RADS is intended to be a "living document" that undergoes continued development to provide up-to-date, evidence based recommendations to achieve its goal of being a tool that imagers can use to communicate with clinicians and to convey concise findings using unambiguous and standardized terminology. Next to its utilization in clinical reporting, CAD-RADS will allow reliable and reproducible data collection, storage and retrieval for future research trials and audits. 
CONCLUSION
In conclusion, CAD-RADS has been developed based on scientific data, expert guidance from leaders in cardiac imaging and a multi-disciplinary effort involving radiology and -Consider symptom-guided anti-ischemic and preventive pharmacotherapy as well as risk factor modification per guideline-directed care*** -Other treatments (including options of revascularization) should be considered per guideline-directed care*** CAD-RADS 5 100% (total occlusion) Total coronary occlusion Consider ICA and/or viability assessment -Consider symptom-guided anti-ischemic and preventive pharmacotherapy as well as risk factors modification per guideline-directed care*** -Other treatments (including options of revascularization) should be considered per guideline-directed care*** CAD-RADS N Non-diagnostic study Obstructive CAD cannot be excluded Additional or alternative evaluation may be needed M A N U S C R I P T
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The CAD-RADS classification should be applied on a per-patient basis for the clinically most relevant (usually highest-grade) stenosis.
All vessels greater than 1.5mm in diameter should be graded for stenosis severity. CAD-RADS will not apply for smaller vessels (<1.5mm in diameter).
* CAD -coronary artery disease ** CAD-RADS 1 -This category should also include the presence of plaque with positive remodeling and no evidence of stenosis *** Guideline-directed care per ACC Stable Ischemic Heart Disease Guidelines (Fihn et al. JACC 2012) (25).
**** ICA -invasive coronary angiography.
MODIFIERS:
If more than one modifier is present, the symbol "/" (slash) should follow each modifier in the following order:
First: modifier N (non-diagnostic)
Second: modifier S (stent)
Third: modifier G (graft)
Fourth: modifier V (vulnerability)
M A N U S C R I P T A C C E P T E D ACS very likely -Consider expedited ICA on a timely basis and revascularization if appropriate if acute occlusion***** -Recommendation for anti-ischemic and preventive management should be considered as well as risk factor modifications.
CAD-RADS N
Non-diagnostic study ACS cannot be excluded
Additional or alternative evaluation for ACS is needed
The CAD-RADS classification should be applied on a per-patient basis for the clinically most relevant (usually highestgrade) stenosis.
* ACS -acute coronary syndrome ** CAD-RADS 1 -This category should also include the presence of plaque with positive remodeling and no evidence of stenosis *** CAD-RADS 2 -Modifier 2/V can be used to indicate vulnerable/ high-risk plaque **** ICA -invasive coronary angiography. ***** Unless the total coronary occlusion can be identified as chronic (through CT and clinical characteristics or patient history)
MODIFIERS:
If more than one modifier is present, the symbol "/" (slash) should follow each modifier in the following order: M A N U S C R I P T A C C E P T E D RCA (left, arrow) , which renders this segment non-diagnostic. There is also stenosis of the mid LAD with 50-69% luminal narrowing (right, arrow), qualifying this lesion as CAD RADS 3. Although the mid RCA segment is non-diagnostic, the presence of suspected obstructive disease within the LAD should be coded as CAD RADS 3/N. If the LAD lesion were mild (less than 50% diameter stenosis), and no other plaques were identified, the patient would be coded as CAD RADS N. Figure 11 . CAD-RADS 4A/S. In-stent stenosis of the proximal LAD with significant luminal narrowing (70-99% stenosis). Grading of in-stent stenosis should follow the grading of normal coronary arteries (0% stenosis, 1-24% stenosis, 25-49% stenosis, 50-69% stenosis, 70-99% stenosis, and >99% stenosis). In this case, severe in-stent restenosis designates a CAD-RADS 4A lesion, which would be followed by the stent modifier "S." M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT Figure 12 . MODIFIER G. Coronary CTA demonstrating a patent left internal mammary artery to the LAD and patent saphenous vein grafts to the ramus intermedius and second obtuse marginal branch. No stenoses or luminal narrowing throughout the grafts (0% stenosis, left). Invasive coronary angiography demonstrating patent LIMA graft to the LAD (right). When evaluating coronary CTA of patients with bypass grafts, the native coronary artery segments proximal to the graft anastamoses should not be evaluated for purposes of CAD RADS coding. Only the grafts and the native coronary artery segments distal to and including the anastomosis should be evaluated for CAD RADS coding. Figure 13 . High-risk plaque features on coronary CTA. These include a) Spotty calcium, defined as punctate calcium within a plaque; b) "napkin ring sign", defined as central low attenuation plaque with a peripheral rim of higher CT attenuation (arrows); c) Positive remodeling, defined as the ratio of outer vessel diameter at the site of plaque divided by the average outer diameter of the proximal and distal vessel greater than 1.1, or Av/[(Ap + Ad)/2] >1.1; and d) Low attenuation plaque, defined as non-calcified plaque with internal attenuation less than 30 HU. Please note that a combination of two or more high-risk features is necessary to designate the plaque as high-risk for CAD-RADS. Figure 14 . CAD-RADS 2/V. Focal non-calcified plaque in the mid RCA with 25-49% diameter stenosis. The plaque demonstrates two high risk features, low attenuation (<30 HU) and positive remodeling, thus coding with the modifier "V." Figure 15 . CAD-RADS 3/S/V. Example demonstrating a patent stent in the proximal RCA (0% stenosis) with high-risk plaque in the proximal LAD resulting in 50-69% stenosis. In isolation, the proximal LAD lesion would be coded CAD RADS 3/V. However, since CAD RADS is coded on a per-patient basis, and a RCA stent is present, this patient would be coded as CAD RADS 3/S/V. 
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FINDINGS:
The total calcium score is zero indicating absence of calcified plaques in the coronary tree.
The coronary arteries arise in normal position. There is ____ (right/ left/ co) coronary artery dominance.
Left main: The left main coronary artery is a _____ (short/ medium/ large) size vessel and (bifurcates in LAD and LCX / or trifurcates in LAD, LCX and RI). It is patent with no evidence of plaque or stenosis. 
